Latest news with #Penumbra
Business Insider
4 days ago
- Business
- Business Insider
Penumbra (PEN) Gets a Buy from RBC Capital
In a report released on July 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Penumbra, with a price target of $330.00. The company's shares closed yesterday at $234.41. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Singh Chadha is an analyst with an average return of -1.0% and a 47.96% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Penumbra with a $316.67 average price target, implying a 35.09% upside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $283.00 price target. Based on Penumbra's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $324.14 million and a net profit of $39.22 million. In comparison, last year the company earned a revenue of $278.66 million and had a net profit of $11 million
Yahoo
11-07-2025
- Business
- Yahoo
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial
Penumbra, Inc. (NYSE:PEN) is one of the The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial has enrolled 100 patients in order to evaluate computer assisted vacuum thrombectomy (CAVT) through utilising Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for treating acute intermediate-high risk pulmonary embolism (PE). An operating theatre showcasing medical solutions from the company. In the US, an estimated 900,000 cases of symptomatic PE take place annually. Pulmonary embolism could be life-threatening, with 10% – 30% of individuals dying within 1 month of diagnosis. Penumbra, Inc. (NYSE:PEN)'s Lightning Flash portfolio happens to be the most advanced mechanical thrombectomy system on the market, focused on addressing venous and pulmonary thrombus. Penumbra, Inc. (NYSE:PEN)'s gross profit for Q1 2025 came in at $215.9 million, or 66.6% of total revenue, compared to $181.1 million, or 65.0% of total revenue, for Q1 2024. This improvement in gross margin was mainly because of favorable product mix throughout the regions and productivity improvements. Penumbra, Inc. (NYSE:PEN) increased its guidance for the U.S. Thrombectomy franchise growth to 20% – 21% YoY from 19% – 20% previously. It reiterated the guidance for gross margin expansion of a minimum of 100 bps in 2025, to over 67% for FY 2025. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a position in Penumbra, Inc. (NYSE:PEN), a leading manufacturer of medical devices that remove blood clots from veins and arteries. Physicians use the company's devices to treat pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia, ischemic stroke, coronary disease, and other conditions. Penumbra's devices, which are called mechanical thrombectomy devices, use computer algorithms to modulate the aspiration power depending on if a clot is detected and to control a separate valve that injects saline to reduce friction between the clot and catheter. This enables a differentiated device profile that maximizes clot removal with speed while decreasing risk of blood loss. While we acknowledge the potential of PEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-07-2025
- Business
- Yahoo
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial
Penumbra, Inc. (NYSE:PEN) is one of the The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial has enrolled 100 patients in order to evaluate computer assisted vacuum thrombectomy (CAVT) through utilising Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for treating acute intermediate-high risk pulmonary embolism (PE). An operating theatre showcasing medical solutions from the company. In the US, an estimated 900,000 cases of symptomatic PE take place annually. Pulmonary embolism could be life-threatening, with 10% – 30% of individuals dying within 1 month of diagnosis. Penumbra, Inc. (NYSE:PEN)'s Lightning Flash portfolio happens to be the most advanced mechanical thrombectomy system on the market, focused on addressing venous and pulmonary thrombus. Penumbra, Inc. (NYSE:PEN)'s gross profit for Q1 2025 came in at $215.9 million, or 66.6% of total revenue, compared to $181.1 million, or 65.0% of total revenue, for Q1 2024. This improvement in gross margin was mainly because of favorable product mix throughout the regions and productivity improvements. Penumbra, Inc. (NYSE:PEN) increased its guidance for the U.S. Thrombectomy franchise growth to 20% – 21% YoY from 19% – 20% previously. It reiterated the guidance for gross margin expansion of a minimum of 100 bps in 2025, to over 67% for FY 2025. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a position in Penumbra, Inc. (NYSE:PEN), a leading manufacturer of medical devices that remove blood clots from veins and arteries. Physicians use the company's devices to treat pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia, ischemic stroke, coronary disease, and other conditions. Penumbra's devices, which are called mechanical thrombectomy devices, use computer algorithms to modulate the aspiration power depending on if a clot is detected and to control a separate valve that injects saline to reduce friction between the clot and catheter. This enables a differentiated device profile that maximizes clot removal with speed while decreasing risk of blood loss. While we acknowledge the potential of PEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Print
05-07-2025
- Business
- The Print
Pakistanis see Microsoft move as more than a corporate exit. ‘So much for economic boom'
'By focusing on tactical incidents like a multinational leaving, people are not focusing on strategic events like Pakistan's DPI (Digital Public Infrastructure) age, which will usher in a multi-hundred billion dollar digital economy,' Habibullah Khan, CEO of Penumbra, a digital design studio, and an expert on Pakistan's digital economy, told The Print. Former Pakistan President Arif Alvi, in a post on X , said that the country was swimming 'in a whirlpool of uncertainty' while tech experts argue that shifts of this sort will not impact Pakistan's tech ecosystem. New Delhi: Microsoft stopped its operations in Pakistan Friday, after a 25-year presence in the country. Pakistanis see it as a sign of the declining economic condition of the country. 'Even global giants like Microsoft find it unsustainable to stay,' Jawwad Rehman, Microsoft's former country head in Pakistan, wrote in a LinkedIn post. Microsoft's departure comes amid a broader wave of restructuring, with the company recently announcing layoffs impacting approximately 9,100 employees worldwide—about 4 per cent of its workforce. Though there was never a full-scale office in the country, it had maintained a liaison setup supporting corporate, educational, governmental, and individual clients. According to Pakistan's IT ministry, the closure aligns with Microsoft's global shift toward a 'partner-led, cloud-first' model. The ministry emphasised that this should not be seen as a total withdrawal but rather a strategic realignment. However, Pakistan represented only an estimated $50 million, or 0.018 per cent of Microsoft's revenue. Many feel the symbolic weight of the company's exit is heavier than the financial figures suggest. Rehman took to LinkedIn to call the move 'more than a corporate exit', describing it as a reflection of a deteriorating environment for foreign businesses. 'We must ask: What changed? What was lost? What happened to the values, leadership, and vision that once made it all possible?' he wrote. Rehman urged Pakistan's IT ministry to engage proactively with Microsoft's global leadership with a bold, KPI-driven roadmap to retain future collaboration. Also read: Punjab govt renames Jinnah heart institute after Maryam Nawaz. Backtracks after backlash A message to investors There are now debates on whose fault it is—an unstable regime, political masters, or a lack of a tech plan. In his X post, Alvi recalled a pivotal moment in February 2022, when Microsoft co-founder Bill Gates visited Pakistan. According to him, Gates had facilitated a direct line between then-Prime Minister Imran Khan and Microsoft CEO Satya Nadella to announce a major investment, a plan that collapsed following the change in government later that year. By October 2022, Microsoft had chosen Vietnam over Pakistan for its regional expansion. 'Regime change upended those plans, and the promise of investment slipped away,' Alvi wrote. 'Pakistan now spirals in a whirlpool of uncertainty. There is increasing joblessness, our talent is migrating abroad, purchasing power has reduced, economic recovery in the 'awami' context feels like a distant & elusive dream,' he added. Khan, however, emphasised a deeper strategic pivot: Pakistan's digital future doesn't hinge solely on the presence of multinational companies. Instead, he pointed to the importance of building robust DPI—platforms for digital identity, payments, and data exchange—as seen in India, Estonia, and Singapore. 'Pakistan's digital stack is nearly complete. Once UPI, digital ID, and data exchange are integrated, we will witness a tech ecosystem boom. We could see a 400 per cent surge in e-commerce and exponential growth in digital payments. That's the real story, not whether Microsoft keeps an office here,' he said. Still, critics argue that Microsoft's exit sends a discouraging message to global investors. Sayed Z Bukhari, former advisor to Imran Khan, noted that just a few years ago, Microsoft was expanding under the PTI government. 'Today, wrong regime, wrong indicators, wrong direction prevail in Pakistan,' he wrote on X. 'This move sends a troubling signal to international investors and raises serious concerns about the country's business climate. When global tech giants exit, it reflects deep-rooted governance and policy issues-a loss that not only damages Pakistan's reputation but also weakens its digital and economic future,' read a post by PTI's Canada handle. Journalist Ihtisham ul Haq wrote a sarcastic message. ''Mulk kaafi oopar jaa raha hai (The country is progressing),'' read the post. Dentist and activist Dr Awab Alvi had something to say about the government. 'So much for the economic boom hype. With Uber & many others exiting, Pakistan's economy is crumbling despite this fascist govt's desperate attempts to convince us otherwise with hollow promises,' he wrote. A parody account of Pakistan COAS Asim Munir on X, referencing Pakistan's turbulent self-image, summed up the mood. 'First Uber, now Microsoft — the great momin nation with Arab-Turkic-Persian-Indus Valley high-IQ white genes… who just dislodged India as Amreeka's BFF.' First Uber, now Microsoft exits Pakistan — the great momin nation with Arab-Turkic-Persian-Indus valley high iq white genes, with no terrorism, winner of every war in history text book and who just dislodged India as Amreeka's BFF 🫠 — Field Marshal Syed Asim Munir's Ego (@JungjooGernail) July 3, 2025 (Edited by Prasanna Bachchhav)
Yahoo
20-06-2025
- Business
- Yahoo
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
